Pluri Inc의 펀더멘털은 비교적 안정적 상태이며, ESG 공시는 업계를 선도하는 수준입니다.성장 잠재력은 상당합니다.기업의 밸류에이션은 적정하게 평가된 것으로 간주되며, 생명공학 및 의료 연구 산업에서 391개 중 160위 랭킹.기관 보유 비율은 매우 높은.지난 한 달 동안 여러 애널리스트가 해당 기업을 매수(으)로 평가했으며, 최고 목표 가격은 12.00입니다.중기적으로 주가는 상승 추세일 것으로 예상됩니다.지난 한 달간 주식 시장에서 부진한 성과를 거두었지만, 기업의 기술적 지표는 탄탄합니다.주가는 지지선과 저항선 사이에서 횡보하고 있으며, 범위 매매 기반의 스윙 트레이딩에 적합한 상황입니다.
Pluri Inc 점수
관련 정보
산업 순위
160 / 391
전체 순위
289 / 4542
산업
생명공학 및 의료 연구
저항선 & 지지선
기업이 아직 관련 데이터를 공개하지 않았습니다.
레이더 차트
현재 가격
과거
미디어 보도
최근 24 시간
보도 수준
매우 낮은
매우 높은
긍정
Pluri Inc 주요 내용
강점위험 요소
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 365.51%의 증가율을 기록했습니다.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.